biostudies-literatureUnknown9Khosravifarsani MTo overcome resistance to chemotherapy for colorectal cancer, we propose to validate <i>in vivo</i> a novel terpyridine-platinum (TP) compound radiolabeled with the radio-theranostic isotope ⁶⁴Cu. <i>In vivo</i> stability, biodistribution, PET imaging, tumor growth delay, toxicity and dosimetry of [⁶⁴Cu]NOTA-C3-TP were determined. The current experimental studies show that [⁶⁴Cu]NOTA-C3-TP is stable <i>in vivo</i>, rapidly eliminated by the kidneys and has a promising tumor uptake ranging from 1.8 ± 0.4 to 3.0 ± 0.2 %ID/g over 48 h. [⁶⁴Cu]NOTA-C3-TP retarded tumor growth by up to 6 ± 2.0 days and improved survival relative to vehicle and non-radioactive [^NatCu]NOTA-C3-TP over 17 days of tumor growth observation. This effect was obtaineFrontiers in medicine975213https://www.ebi.ac.uk/biostudies/studies/S-EPMC9549809biostudies-literature<i>In vivo</i> behavior of [⁶⁴Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer.PMC9549809Ait-Mohand SPaquette BSanche LKhosravifarsani MGuerin Bfalse<i>In vivo</i> behavior of [⁶⁴Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer.To overcome resistance to chemotherapy for colorectal cancer, we propose to validate <i>in vivo</i> a novel terpyridine-platinum (TP) compound radiolabeled with the radio-theranostic isotope ⁶⁴Cu. <i>In vivo</i> stability, biodistribution, PET imaging, tumor growth delay, toxicity and dosimetry of [⁶⁴Cu]NOTA-C3-TP were determined. The current experimental studies show that [⁶⁴Cu]NOTA-C3-TP is stable <i>in vivo</i>, rapidly eliminated by the kidneys and has a promising tumor uptake ranging from 1.8 ± 0.4 to 3.0 ± 0.2 %ID/g over 48 h. [⁶⁴Cu]NOTA-C3-TP retarded tumor growth by up to 6 ± 2.0 days and improved survival relative to vehicle and non-radioactive [^NatCu]NOTA-C3-TP over 17 days of tumor growth observation. This effect was obtaine2022-01-01T00:00:00Z20222025-04-04T21:41:13.435Z2025-04-04T21:41:13.435ZS-EPMC95498093622615610.3389/fmed.2022.975213